HCRP1 expression status is a significant prognostic marker in oral and oropharyngeal cancer

Oral Diseases

Volumn 19, Issue 2, 2013, Pages 206-211

  Perisanidis, C ^a   Savarese Brenner, B ^a   Wurger T ^a   Wrba, F ^a   Huynh, A ^a   Schopper, C ^a   Kornek, G ^a   Selzer, E ^a   Ewers, R ^a   Psyrri, A ^b   Krainer, M ^a   Filipits, M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Epidermal growth factor receptor; HCRP1; Immunohis tochemistry; Oral and oropharyngeal cancer; Prognosis

Indexed keywords

FLUOROURACIL; HEPATOCELLULAR CARCINOMA RELATED PROTEIN 1; MITOMYCIN; PEPTIDES AND PROTEINS; UNCLASSIFIED DRUG; ESCRT PROTEIN; VPS37A PROTEIN, HUMAN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BOLUS INJECTION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTINUOUS INFUSION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; MULTIMODALITY CANCER THERAPY; ORAL AND OROPHARYNGEAL SQUAMOUS CELL CARCINOMA; OROPHARYNX CANCER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE DISTRIBUTION; RECURRENCE FREE SURVIVAL; TREATMENT RESPONSE; TUMOR BIOPSY; CARCINOMA, SQUAMOUS CELL; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; MORTALITY; MOUTH NEOPLASMS; OROPHARYNGEAL NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; YOUNG ADULT;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; ENDOSOMAL SORTING COMPLEXES REQUIRED FOR TRANSPORT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; OROPHARYNGEAL NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84878119052     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2012.01972.x     Document Type: Article

References (32)

1. Bache KG, Slagsvold T, Cabezas A et al (2004). The Growth-regulatory protein HCRP1/h Vps37A is a subunit of mammalian ESCRT-I and mediates receptor down-regulation. Mol Biol Cell 15: 4337-4346.
2. Barnes CJ, Ohshiro K, Rayala SK et al (2007). Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res 13: 4291-4299.
3. Braun OM, Neumeister B, Popp W et al (1989). Histologic tumor regression grades in squamous cell carcinoma of the head and neck after preoperative radiochemotherapy. Cancer 63: 1097-1100.
4. Chen LF, Cohen EE, Grandis JR (2010). New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. Clin Cancer Res 16: 2489-2495.
5. Ciardiello F, Tortora G (2003). Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer 39: 1348-1354.
6. Cohen EE (2006). Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 24: 2659-2665.
7. Cohen EE, Rosen F, Stadler WM et al (2003). Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21: 1980-1987.
8. Diniz-Freitas M, Garcia-Caballero T, Antunez-Lopez J et al (2007). Pharmacodiagnostic evaluation of EGFR expression in oral squamous cell carcinoma. Oral Dis 13: 285-290.
9. Driemel O, Ettl T, Kolbl O, et al (2009). Outcome and histopathologic regression in oral squamous cell carcinoma after preoperative radiochemotherapy. Strahlenther Onkol 185: 296-302.
10. Egloff AM, Grandis JR (2008). Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer. Semin Oncol 35: 286-297.
11. Eich HT, Loschcke M, Scheer M et al (2008). Neoadjuvant radiochemotherapy and radical resection for advanced squamous cell carcinoma of the oral cavity. Strahlenther Onkol 184: 23-29.
12. Farshadpour F, Hordijk GJ, Koole R et al (2007). Non-smoking and non-drinking patients with head and neck squamous cell carcinoma: a distinct population. Oral Dis 13: 239-243.
13. Ferlay J, Shin HR, Bray F et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
14. Kalyankrishna S, Grandis JR (2006). Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 24: 2666-2672.
15. Karamouzis MV, Grandis JR, Argiris A (2007). Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA 298: 70-82.
16. Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG (2009). Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors. Lancet Oncol 10: 709-717.
17. Katzmann DJ, Odorizzi G, Emr SD (2002). Receptor downregulation and multivesicular-body sorting. Nat Rev Mol Cell Biol 3: 893-905.
18. Kostelansky MS, Schluter C, Tam YY et al (2007). Molecular architecture and functional model of the complete yeast ESCRT-I heterotetramer. Cell 129: 485-498.
19. Lai MW, Huang SF, Lin SM et al (2009). Expression of the HCRP1 mRNA in HCC as an independent predictor of disease-free survival after surgical resection. Hepatol Res 39: 164-176.
20. Pao W, Miller VA, Politi KA et al (2005). Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73.
21. Perisanidis C, Perisanidis B, Wrba F et al (2012). Evaluation of immunohistochemical expression of p53, p21, p27, cyclin D1, and Ki67 in oral and oropharyngeal squamous cell carcinoma. J Oral Pathol Med 41: 40-46.
22. Pindborg JJ, Reichart PA, Smith CJ, Van der Waal I (1997). Histological typing of cancer and precancer of the oral mucosa. World Health Organization international histological classification of tumors. Springer: Berlin.
23. Rubin Grandis J, Melhem MF, Gooding WE et al (1998). Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90: 824-832.
24. Scully C, Bagan J (2009a). Oral squamous cell carcinoma overview. Oral Oncol 45: 301-308.
25. Scully C, Bagan J (2009b). Oral squamous cell carcinoma: overview of current understanding of aetiopathogenesis and clinical implications. Oral Dis 15: 388-399.
26. Silva SD, Cunha IW, Younes RN et al (2010). ErbB receptors and fatty acid synthase expression in aggressive head and neck squamous cell carcinomas. Oral Dis 16: 774-780.
27. Sobin LH, Wittekind C (2002). International Union Against Cancer (UICC) TNM classification of malignant tumours, 6th edn. Wiley: New York.
28. Soulieres D, Senzer NN, Vokes EE et al (2004). Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22: 77-85.
29. Vermorken JB, Specenier P (2010). Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol 21(Suppl 7): vii252-vii261.
30. Vermorken JB, Mesia R, Rivera F et al (2008). Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359: 1116-1127.
31. Wheeler DL, Huang S, Kruser TJ et al (2008). Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 27: 3944-3956.
32. Wittinger M, Vanhara P, El-Gazzar A et al (2011). hVps37A status affects prognosis and cetuximab sensitivity in ovarian cancer. Clin Cancer Res 17: 7816-7827.